Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Next Previous
X
Search
Trial Profile

Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Intestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms CLARINET open-label extension study
  • Sponsors Ipsen

    • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jun 2017 Results of final progression free survival analyses for subgroups (according to tumor origin and prior therapy), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2017 According to an Ipsen media release, final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors will be presented at the American Society of Clinical Oncology (ASCO) 2017 conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top